CL2008003773A1 - Compuestos derivados de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida; composicion farmaceutica que lo comprende; y uso para tratar o prevenir una enfermedad provocada por una reduccion o desequilibrio de la funcion del receptor de glutamato, tal como esquizofrenia. - Google Patents

Compuestos derivados de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida; composicion farmaceutica que lo comprende; y uso para tratar o prevenir una enfermedad provocada por una reduccion o desequilibrio de la funcion del receptor de glutamato, tal como esquizofrenia.

Info

Publication number
CL2008003773A1
CL2008003773A1 CL2008003773A CL2008003773A CL2008003773A1 CL 2008003773 A1 CL2008003773 A1 CL 2008003773A1 CL 2008003773 A CL2008003773 A CL 2008003773A CL 2008003773 A CL2008003773 A CL 2008003773A CL 2008003773 A1 CL2008003773 A1 CL 2008003773A1
Authority
CL
Chile
Prior art keywords
propanesulfonamide
inden
schizophrenia
imbalance
dihydro
Prior art date
Application number
CL2008003773A
Other languages
English (en)
Inventor
Nicolas Bertheleme
Wai Ngor Chan
Jaqueline Sandra Scott
Simon E Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0724783A external-priority patent/GB0724783D0/en
Priority claimed from GB0818068A external-priority patent/GB0818068D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2008003773A1 publication Critical patent/CL2008003773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto derivado de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida, composición farmacutica que lo comprende y su uso para tratar o prevenir una enfermedad provocada por una reducción o desequilibrio de la función del receptor de glutamato, tal como esquizofrenia.
CL2008003773A 2007-12-19 2008-12-17 Compuestos derivados de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida; composicion farmaceutica que lo comprende; y uso para tratar o prevenir una enfermedad provocada por una reduccion o desequilibrio de la funcion del receptor de glutamato, tal como esquizofrenia. CL2008003773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0724783A GB0724783D0 (en) 2007-12-19 2007-12-19 Compounds
GB0818068A GB0818068D0 (en) 2008-10-02 2008-10-02 Compounds

Publications (1)

Publication Number Publication Date
CL2008003773A1 true CL2008003773A1 (es) 2010-03-05

Family

ID=40566351

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003773A CL2008003773A1 (es) 2007-12-19 2008-12-17 Compuestos derivados de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida; composicion farmaceutica que lo comprende; y uso para tratar o prevenir una enfermedad provocada por una reduccion o desequilibrio de la funcion del receptor de glutamato, tal como esquizofrenia.

Country Status (9)

Country Link
US (1) US8173820B2 (es)
EP (1) EP2222632A1 (es)
JP (1) JP2011506551A (es)
AR (1) AR069781A1 (es)
CL (1) CL2008003773A1 (es)
PE (1) PE20091086A1 (es)
TW (1) TW200940491A (es)
UY (1) UY31544A1 (es)
WO (1) WO2009080637A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
GB0821166D0 (en) * 2008-11-19 2008-12-24 Glaxo Group Ltd Compounds
EP2417101B1 (en) 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
JP6319805B2 (ja) * 2014-10-08 2018-05-09 田岡化学工業株式会社 スピロビフルオレン骨格を有するジオール化合物およびその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525099B1 (en) * 1998-07-31 2003-02-25 Eli Lilly And Company N-substituted sulfonamide derivatives
KR20070050070A (ko) 2004-08-09 2007-05-14 글락소 그룹 리미티드 글루타메이트 수용체를 강화시키는 화합물 및 의약에서의그의 용도
GB0417709D0 (en) * 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
AR069781A1 (es) 2010-02-17
WO2009080637A1 (en) 2009-07-02
EP2222632A1 (en) 2010-09-01
US8173820B2 (en) 2012-05-08
TW200940491A (en) 2009-10-01
JP2011506551A (ja) 2011-03-03
UY31544A1 (es) 2009-07-17
US20110021578A1 (en) 2011-01-27
PE20091086A1 (es) 2009-08-23

Similar Documents

Publication Publication Date Title
CL2007003061A1 (es) Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CL2008003773A1 (es) Compuestos derivados de n-[(2s)-5-(oxi-sustituido)-2,3-dihidro-1h-inden-2-il]-2-propanosulfonamida; composicion farmaceutica que lo comprende; y uso para tratar o prevenir una enfermedad provocada por una reduccion o desequilibrio de la funcion del receptor de glutamato, tal como esquizofrenia.
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
CL2007003565A1 (es) Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih.
CL2008000862A1 (es) Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1.
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
CL2010001468A1 (es) Compuestos derivados de adamantildiamida, moduladores alostericos del receptor 5 glutamato metabotropico (mglur5); composicion farmaceutica que los comprende; y uso para tratar una enfermedad o trastorno del snc tal como depresion, ansiedad, esquizofrenia y enfermedad de parkinson.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
MX384206B (es) Formulaciones de inhibidores de dpp iv
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
CL2007003033A1 (es) Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2007003212A1 (es) Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
CL2008000585A1 (es) Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.